Market closedNon-fractional

BioXcel Therapeutics/BTAI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Ticker

BTAI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

New Haven, United States

Employees

74

BTAI Metrics

BasicAdvanced
$39M
Market cap
-
P/E ratio
-$5.15
EPS
0.36
Beta
-
Dividend rate
$39M
0.36
2.57
2.367
-140.933
-141.42
-10.37%
-66.96%
1,581.24%
17.754
-0.48
-0.48
-0.259
202.24%
-22.37%
8.30%

What the Analysts think about BTAI

Analyst Ratings

Majority rating from 7 analysts.
Buy

BTAI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,340.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
66.67%
Net income
-$27M
20.27%
Profit margin
-5,340.00%
-27.84%

BTAI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 24.58%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.83
-$1.72
-$0.76
-$0.87
-
Expected
-$1.75
-$1.30
-$0.91
-$0.70
-$0.71
Surprise
4.52%
31.90%
-16.48%
24.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BioXcel Therapeutics stock?

BioXcel Therapeutics (BTAI) has a market cap of $39M as of July 06, 2024.

What is the P/E ratio for BioXcel Therapeutics stock?

The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of July 06, 2024.

Does BioXcel Therapeutics stock pay dividends?

No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next BioXcel Therapeutics dividend payment date?

BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.

What is the beta indicator for BioXcel Therapeutics?

BioXcel Therapeutics (BTAI) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell BioXcel Therapeutics stock

Buy or sell BioXcel Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing